Open AccessAntibodies to Platelet Factor 4–Heparin Complex and Outcome in Hemodialysis Patients with Diabetes
Author(s) -
Vera Krane,
Mario Berger,
Jürgen Lilienthal,
Karl Winkler,
C. M. Schambeck,
Christoph Wanner
Publication year - 2010
Publication title -
clinical journal of the american society of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.755
H-Index - 151
eISSN - 1555-905X
pISSN - 1555-9041
DOI - 10.2215/cjn.01170209
Subject(s) - medicine , heparin , hemodialysis , diabetes mellitus , platelet factor 4 , antibody , platelet , heparin induced thrombocytopenia , intensive care medicine , cardiology , immunology , endocrinology
Hemodialysis patients with type 2 diabetes exhibit an excessive cardiovascular risk and regularly receive heparin. We tested whether antibodies to the platelet factor 4-heparin complex (PF4-H-AB) contribute to outcome.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom